# An Italian Multicentric Retrospective Observational Study to Assess Effectiveness and Safety of the Combination of Tafasitamab and Lenalidomide in Diffuse Large B-cell Lymphoma Patients Treated Under Named Patient Program

> **NCT06782789** · — · RECRUITING · sponsor: **IRCCS Azienda Ospedaliero-Universitaria di Bologna** · enrollment: 96 (estimated)

## Conditions studied

- Diffuse Large B Cell Lymphoma (DLBCL)

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06782789
- **Lead sponsor:** IRCCS Azienda Ospedaliero-Universitaria di Bologna
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-01
- **Primary completion:** 2026-08
- **Final completion:** 2026-08
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2025-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06782789

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06782789, "An Italian Multicentric Retrospective Observational Study to Assess Effectiveness and Safety of the Combination of Tafasitamab and Lenalidomide in Diffuse Large B-cell Lymphoma Patients Treated Under Named Patient Program". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06782789. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*